ASCO 2021 Lymphoma
Incorporating New Targeted Therapies for Indolent B-Cell Lymphomas
Jul 1, 2021
For a presentation at ASCO 2021, John Seymour, PhD, Professor at the Peter MacCallum Cancer Centre of the Royal Melbourne Hospital and University of Melbourne in Australia, discussed six FDA-approved agents or drug...
Read MoreConsidering Cellular Therapy for Follicular Lymphoma
Jul 1, 2021
For a review presented at ASCO 2021, Sonali M. Smith, MD, FASCO, Elwood V. Jensen Professor in Medicine and Chief of the Section of Hematology/Oncology at the University of Chicago, discussed the findings of two studies focused...
Read MoreEncouraging Safety & Efficacy Profile for Mono- & Combination Therapy With TG-1701
Jul 1, 2021
TG-1701 (TG Therapeutics) is an investigational, once-daily, selective, convalent, oral Bruton tyrosine kinase inhibitor. Prior research has shown that inhibition of Bruton tyrosine kinase is superior to standard...
Read MoreEncouraging Safety & Efficacy with for Mono/Combo TG-1701 Therapy
Jun 23, 2021
TG-1701 (TG Therapeutics) is an investigational, once-daily, selective, convalent, oral Bruton tyrosine kinase inhibitor. Prior research has shown that inhibition of Bruton tyrosine kinase is superior to standard...
Read MoreMolecular tumor profiling has a significant impact on diagnosis and treatment of young patients with solid tumors
Jun 15, 2021
First results of the GAIN/iCAT2 Consortium trial show the importance of molecular profiling of solid tumors in young patients. Next generation sequencing (NGS) assays are now a standard part of clinical care for many adult solid...
Read MoreGood Survival, Poor Complication Rates for Elderly with Aggressive NHL
Jun 4, 2021
Evidence indicates that balancing treatment efficacy with complication risk is critically important for older adults with non-Hodgkin’s lymphoma (NHL); however, the survival outcomes, rates of toxicities, and healthcare...
Read MoreSalvage Therapy-Related Survival Predictors Identified for Relapsed/Refractory Classic Hodgkin’s Lymphoma
Jun 4, 2021
Although previous studies suggest positive outcomes with novel salvage therapies for patients with relapsed/refractory classic Hodgkin’s lymphoma who are eligible for autologous stem cell transplant, the efficacies and outcomes...
Read MoreStudy Quantifies Secondary Malignancy Risk in non-Hodgkin’s Lymphoma Survivors
Jun 4, 2021
Prior research indicates that survivors of non-Hodgkin’s lymphoma are at increased risk of secondary malignancies. However, data are lacking on long-term risk and whether such risk differs by treatment modality. Investigators...
Read MoreBaseline Tumor Burden a Potential Predictor of Disease Progression in DLBCL & HL
Jun 4, 2021
To determine whether a correlation exists between baseline tumor burden and early tumor progression based on imaging in patients with diffuse large B-cell lymphoma (DLBCL) and Hodgkin’s lymphoma (HL), researchers analyzed...
Read MoreTrends in Treatment & Outcomes for Patients with Follicular Lymphoma
Jun 4, 2021
With limited data on the real-world treatment of follicular lymphoma in a contemporary cohort of patients, researchers examined treatment patterns and outcomes among nearly 2,400 adult patients with an initial follicular...
Read MoreAn Insider’s Guide to ASCO 2021: A Focus on Lymphoma
Jun 3, 2021
The ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...
Read More